Titre :
  • Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Auteur : Piccart-Gebhart, Martine ; Bertelsen, K ; James, K ; Cassidy, J ; Mangioni, C ; Simonsen, E ; Stuart, G ; Kaye, Steve ; Vergote, Ignace ; Blom, R ; Grimshaw, R ; Atkinson, R J ; Swenerton, K D ; Trope, C ; Nardi, M ; Kaern, J ; Tumolo, Salvatore ; Timmers, P ; Roy, J A ; Lhoas, F ; Lindvall, B ; Bacon, M ; Birt, A ; Andersen, J E ; Zee, B ; Paul, J ; Baron, Benoît ; Pecorelli, Sërgio
Informations sur la publication : Journal of the National Cancer Institute, 92, 9, (page 699-708)
Statut de publication : Publié, 2000-05
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Adult
Aged
Aged, 80 and over
Alopecia -- chemically induced
Antineoplastic Combined Chemotherapy Protocols -- adverse effects
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Cisplatin -- administration & dosage
Cisplatin -- adverse effects
Combined Modality Therapy
Cross-Over Studies
Cyclophosphamide -- administration & dosage
Cyclophosphamide -- adverse effects
Disease Progression
Female
Follow-Up Studies
Humans
Middle Aged
Nausea -- chemically induced
Neoplasm Staging
Neutropenia -- chemically induced
Ovarian Neoplasms -- drug therapy
Ovarian Neoplasms -- mortality
Ovarian Neoplasms -- surgery
Paclitaxel -- administration & dosage
Paclitaxel -- adverse effects
Survival Analysis
Thrombocytopenia -- chemically induced
Time Factors
Treatment Outcome
Vomiting -- chemically induced
Note : Clinical Trial
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:0027-8874 
info:pmid/10793106